Avi Ashkenazi

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jin Zhaoyu; Li Yun; Pitti Robert; Lawrence David; Pham Victoria C; Lill Jennie R; Ashkenazi Avi
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.
Qing Jing; Du Xiangnan; Chen Yongmei; Chan Pamela; Li Hao; Wu Ping; Marsters Scot; Stawicki Scott; Tien Janet; Totpal Klara; Ross Sarajane; Stinson Susanna; Dornan David; French Dorothy; Wang Qian-Rena; Stephan Jean-Philippe; Wu Yan; Wiesmann Christian; Ashkenazi Avi
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Wilson Nicholas S; Dixit Vishva; Ashkenazi Avi
Death receptor signal transducers: nodes of coordination in immune signaling networks.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Avi Ashkenazi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jin Zhaoyu; Li Yun; Pitti Robert; Lawrence David; Pham Victoria C; Lill Jennie R; Ashkenazi Avi
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.
Cell 2009;137(4):721-35.
2009: Qing Jing; Du Xiangnan; Chen Yongmei; Chan Pamela; Li Hao; Wu Ping; Marsters Scot; Stawicki Scott; Tien Janet; Totpal Klara; Ross Sarajane; Stinson Susanna; Dornan David; French Dorothy; Wang Qian-Rena; Stephan Jean-Philippe; Wu Yan; Wiesmann Christian; Ashkenazi Avi
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
The Journal of clinical investigation 2009;119(5):1216-29.
2009: Wilson Nicholas S; Dixit Vishva; Ashkenazi Avi
Death receptor signal transducers: nodes of coordination in immune signaling networks.
Nature immunology 2009;10(4):348-55.
2008: Jin Hongkui; Yang Renhui; Ross Jed; Fong Sharon; Carano Richard; Totpal Klara; Lawrence David; Zheng Zhong; Koeppen Hartmut; Stern Howard; Schwall Ralph; Ashkenazi Avi
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7733-40.
2008: Ashkenazi Avi
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
Nature reviews. Drug discovery 2008;7(12):1001-12.
2008: Shang Yonglei; Mao Yifan; Batson Jennifer; Scales Suzie J; Phillips Gail; Lackner Mark R; Totpal Klara; Williams Simon; Yang Jihong; Tang Zhijun; Modrusan Zora; Tan Christine; Liang Wei-Ching; Tsai Siao Ping; Vanderbilt Alexander; Kozuka Kenji; Hoeflich Klaus; Tien Janet; Ross Sarajane; Li Congfen; Lee Sang Hoon; Song An; Wu Yan; Stephan Jean-Philippe; Ashkenazi Avi; Zha Jiping
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
Molecular cancer therapeutics 2008;7(9):2599-608.
2008: Ashkenazi Avi; Holland Pamela; Eckhardt S Gail
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3621-30.
2008: Ashkenazi Avi
Targeting the extrinsic apoptosis pathway in cancer.
Cytokine & growth factor reviews 2008;19(3-4):325-31.
2008: Desnoyers L R; Pai R; Ferrando R E; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French D M
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Oncogene 2008;27(1):85-97.
2007: Daniel Dylan; Yang Becky; Lawrence David A; Totpal Klara; Balter Inessa; Lee Wyne P; Gogineni Alvin; Cole Mary J; Yee Sharon Fong; Ross Sarajane; Ashkenazi Avi
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Blood 2007;110(12):4037-46.
2007: Wagner Klaus W; Punnoose Elizabeth A; Januario Thomas; Lawrence David A; Pitti Robert M; Lancaster Kate; Lee Dori; von Goetz Melissa; Yee Sharon Fong; Totpal Klara; Huw Ling; Katta Viswanatham; Cavet Guy; Hymowitz Sarah G; Amler Lukas; Ashkenazi Avi
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Nature medicine 2007;13(9):1070-7.
2007: Holst Charles R; Bou-Reslan Hani; Gore Bryan B; Wong Karen; Grant Deanna; Chalasani Sreedevi; Carano Richard A; Frantz Gretchen D; Tessier-Lavigne Marc; Bolon Brad; French Dorothy M; Ashkenazi Avi
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival.
PloS one 2007;2(6):e575.
2006: Eimon P M; Kratz E; Varfolomeev E; Hymowitz S G; Stern H; Zha J; Ashkenazi A
Delineation of the cell-extrinsic apoptosis pathway in the zebrafish.
Cell death and differentiation 2006;13(10):1619-30.
2006: Kratz E; Eimon P M; Mukhyala K; Stern H; Zha J; Strasser A; Hart R; Ashkenazi A
Functional characterization of the Bcl-2 gene family in the zebrafish.
Cell death and differentiation 2006;13(10):1631-40.
2006: Li Bing; Russell Stephen J; Compaan Deanne M; Totpal Klara; Marsters Scot A; Ashkenazi Avi; Cochran Andrea G; Hymowitz Sarah G; Sidhu Sachdev S
Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists.
Journal of molecular biology 2006;361(3):522-36.
2006: Austin Cary D; Lawrence David A; Peden Andrew A; Varfolomeev Eugene E; Totpal Klara; De Mazière Ann M; Klumperman Judith; Arnott David; Pham Victoria; Scheller Richard H; Ashkenazi Avi
Death-receptor activation halts clathrin-dependent endocytosis.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10283-8.
2005: Hymowitz Sarah G; Ashkenazi Avi
Toward small-molecule agonists of TNF receptors.
Nature chemical biology 2005;1(7):353-4.
2005: Maecker Heather; Varfolomeev Eugene; Kischkel Frank; Lawrence David; LeBlanc Heidi; Lee Wyne; Hurst Stephen; Danilenko Dimitry; Li Jun; Filvaroff Ellen; Yang Becky; Daniel Dylan; Ashkenazi Avi
TWEAK attenuates the transition from innate to adaptive immunity.
Cell 2005;123(5):931-44.
2005: Varfolomeev Eugene; Maecker Heather; Sharp Darcie; Lawrence David; Renz Mark; Vucic Domagoj; Ashkenazi Avi
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
The Journal of biological chemistry 2005;280(49):40599-608.
2005: Cretney Erika; McQualter Jonathan L; Kayagaki Nobuhiko; Yagita Hideo; Bernard Claude C A; Grewal Iqbal S; Ashkenazi Avi; Smyth Mark J
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.
Immunology and cell biology 2005;83(5):511-9.
2005: Sharp Darcie A; Lawrence David A; Ashkenazi Avi
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis.
The Journal of biological chemistry 2005;280(19):19401-9.
2005: Kelley Robert F; Totpal Klara; Lindstrom Stephanie H; Mathieu Mary; Billeci Karen; Deforge Laura; Pai Roger; Hymowitz Sarah G; Ashkenazi Avi
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.
The Journal of biological chemistry 2005;280(3):2205-12.
2004: Jin Hongkui; Yang Renhui; Fong Sharon; Totpal Klara; Lawrence David; Zheng Zhong; Ross Jed; Koeppen Hartmut; Schwall Ralph; Ashkenazi Avi
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Cancer research 2004;64(14):4900-5.
2004: Varfolomeev Eugene E; Ashkenazi Avi
Tumor necrosis factor: an apoptosis JuNKie?
Cell 2004;116(4):491-7.
2004: Varfolomeev Eugene; Kischkel Frank; Martin Flavius; Seshasayee Dhaya; Wang Hua; Lawrence David; Olsson Christine; Tom Lucrece; Erickson Sharon; French Dorothy; Schow Peter; Grewal Iqbal S; Ashkenazi Avi
APRIL-deficient mice have normal immune system development.
Molecular and cellular biology 2004;24(3):997-1006.
2003: Miller Kathy; Meng Gloria; Liu Jun; Hurst Amy; Hsei Vanessa; Wong Wai-Lee; Ekert Rene; Lawrence David; Sherwood Steven; DeForge Laura; Gaudreault Jacques; Keller Gilbert; Sliwkowski Mark; Ashkenazi Avi; Presta Leonard
Design, construction, and in vitro analyses of multivalent antibodies.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(9):4854-61.
2003: LeBlanc H N; Ashkenazi A
Apo2L/TRAIL and its death and decoy receptors.
Cell death and differentiation 2003;10(1):66-75.
2002: Ashkenazi Avi
Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
Nature reviews. Cancer 2002;2(6):420-30.
2002: LeBlanc Heidi; Lawrence David; Varfolomeev Eugene; Totpal Klara; Morlan John; Schow Peter; Fong Sharon; Schwall Ralph; Sinicropi Dominick; Ashkenazi Avi
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
Nature medicine 2002;8(3):274-81.
2001: Kischkel F C; Lawrence D A; Tinel A; LeBlanc H; Virmani A; Schow P; Gazdar A; Blenis J; Arnott D; Ashkenazi A
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.
The Journal of biological chemistry 2001;276(49):46639-46.
2001: Wang H; Marsters S A; Baker T; Chan B; Lee W P; Fu L; Tumas D; Yan M; Dixit V M; Ashkenazi A; Grewal I S
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice.
Nature immunology 2001;2(7):632-7.
2001: Chuntharapai A; Dodge K; Grimmer K; Schroeder K; Marsters S A; Koeppen H; Ashkenazi A; Kim K J
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(8):4891-8.
2001: Lawrence D; Shahrokh Z; Marsters S; Achilles K; Shih D; Mounho B; Hillan K; Totpal K; DeForge L; Schow P; Hooley J; Sherwood S; Pai R; Leung S; Khan L; Gliniak B; Bussiere J; Smith C A; Strom S S; Kelley S; Fox J A; Thomas D; Ashkenazi A
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.
Nature medicine 2001;7(4):383-5.
2000: Kischkel F C; Ashkenazi A
Combining enhanced metabolic labeling with immunoblotting to detect interactions of endogenous cellular proteins.
BioTechniques 2000;29(3):506-10, 512.
2000: Yan M; Marsters S A; Grewal I S; Wang H; Ashkenazi A; Dixit V M
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity.
Nature immunology 2000;1(1):37-41.
2000: Marsters S A; Yan M; Pitti R M; Haas P E; Dixit V M; Ashkenazi A
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.
Current biology : CB 2000;10(13):785-8.
2000: Kischkel F C; Lawrence D A; Chuntharapai A; Schow P; Kim K J; Ashkenazi A
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.
Immunity 2000;12(6):611-20.
2000: Hymowitz S G; O'Connell M P; Ultsch M H; Hurst A; Totpal K; Ashkenazi A; de Vos A M; Kelley R F
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.
Biochemistry 2000;39(4):633-40.
1999: Hymowitz S G; Christinger H W; Fuh G; Ultsch M; O'Connell M; Kelley R F; Ashkenazi A; de Vos A M
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
Molecular cell 1999;4(4):563-71.
1999: Ashkenazi A; Pai R C; Fong S; Leung S; Lawrence D A; Marsters S A; Blackie C; Chang L; McMurtrey A E; Hebert A; DeForge L; Koumenis I L; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall R H
Safety and antitumor activity of recombinant soluble Apo2 ligand.
The Journal of clinical investigation 1999;104(2):155-62.
1999: Chuntharapai A; Gibbs V; Lu J; Ow A; Marsters S; Ashkenazi A; De Vos A; Jin Kim K
Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(2):766-73.
1999: Ashkenazi A; Dixit V M
Apoptosis control by death and decoy receptors.
Current opinion in cell biology 1999;11(2):255-60.
1999: Gurney A L; Marsters S A; Huang R M; Pitti R M; Mark D T; Baldwin D T; Gray A M; Dowd A D; Brush A D; Heldens A D; Schow A D; Goddard A D; Wood W I; Baker K P; Godowski P J; Ashkenazi A
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR.
Current biology : CB 1999;9(4):215-8.
1999: Marsters S A; Pitti R A; Sheridan J P; Ashkenazi A
Control of apoptosis signaling by Apo2 ligand.
Recent progress in hormone research 1999;54():225-34.
1998: Pitti R M; Marsters S A; Lawrence D A; Roy M; Kischkel F C; Dowd P; Huang A; Donahue C J; Sherwood S W; Baldwin D T; Godowski P J; Wood W I; Gurney A L; Hillan K J; Cohen R L; Goddard A D; Botstein D; Ashkenazi A
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
Nature 1998;396(6712):699-703.
1998: Ashkenazi A; Dixit V M
Death receptors: signaling and modulation.
Science (New York, N.Y.) 1998;281(5381):1305-8.
1998: Marsters S A; Sheridan J P; Pitti R M; Brush J; Goddard A; Ashkenazi A
Identification of a ligand for the death-domain-containing receptor Apo3.
Current biology : CB 1998;8(9):525-8.
1997: Marsters S A; Sheridan J P; Pitti R M; Huang A; Skubatch M; Baldwin D; Yuan J; Gurney A; Goddard A D; Godowski P; Ashkenazi A
A novel receptor for Apo2L/TRAIL contains a truncated death domain.
Current biology : CB 1997;7(12):1003-6.
1997: Sheridan J P; Marsters S A; Pitti R M; Gurney A; Skubatch M; Baldwin D; Ramakrishnan L; Gray C L; Baker K; Wood W I; Goddard A D; Godowski P; Ashkenazi A
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
Science (New York, N.Y.) 1997;277(5327):818-21.
1997: Marsters S A; Ayres T M; Skubatch M; Gray C L; Rothe M; Ashkenazi A
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1.
The Journal of biological chemistry 1997;272(22):14029-32.
1997: Ashkenazi A; Chamow S M
Immunoadhesins as research tools and therapeutic agents.
Current opinion in immunology 1997;9(2):195-200.
1996: Marsters S A; Sheridan J P; Donahue C J; Pitti R M; Gray C L; Goddard A D; Bauer K D; Ashkenazi A
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B.
Current biology : CB 1996;6(12):1669-76.
1996: Marsters S A; Pitti R M; Donahue C J; Ruppert S; Bauer K D; Ashkenazi A
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.
Current biology : CB 1996;6(6):750-2.
1996: Pitti R M; Marsters S A; Ruppert S; Donahue C J; Moore A; Ashkenazi A
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.
The Journal of biological chemistry 1996;271(22):12687-90.
1996: Van Zee K J; Moldawer L L; Oldenburg H S; Thompson W A; Stackpole S A; Montegut W J; Rogy M A; Meschter C; Gallati H; Schiller C D; Richter W F; Loetscher H; Ashkenazi A; Chamow S M; Wurm F; Calvano S E; Lowry S F; Lesslauer W
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(6):2221-30.
1995: Chamow S M; Zhang D; Tan X Y; Mhatre S M; Marsters S A; Peers D H; Byrn R A; Ashkenazi A; Junghans R P
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Journal of hematotherapy 1995;4(5):439-46.
1995: Marsters S A; Pennica D; Bach E; Schreiber R D; Ashkenazi A
Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(12):5401-5.
1995: Oksenberg D; Havlik S; Peroutka S J; Ashkenazi A
The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity.
Journal of neurochemistry 1995;64(4):1440-7.
1994: Pitti R M; Marsters S A; Haak-Frendscho M; Osaka G C; Mordenti J; Chamow S M; Ashkenazi A
Molecular and biological properties of an interleukin-1 receptor immunoadhesin.
Molecular immunology 1994;31(17):1345-51.
1994: Beck J T; Marsters S A; Harris R J; Carter P; Ashkenazi A; Chamow S M
Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage.
Molecular immunology 1994;31(17):1335-44.
1994: Jin H; Yang R; Marsters S A; Bunting S A; Wurm F M; Chamow S M; Ashkenazi A
Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody.
The Journal of infectious diseases 1994;170(5):1323-6.
1994: Chamow S M; Zhang D Z; Tan X Y; Mhatre S M; Marsters S A; Peers D H; Byrn R A; Ashkenazi A; Junghans R P
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(9):4268-80.
1994: Chamow S M; Kogan T P; Venuti M; Gadek T; Harris R J; Peers D H; Mordenti J; Shak S; Ashkenazi A
Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation.
Bioconjugate chemistry 1994;5(2):133-40.
1994: Haak-Frendscho M; Marsters S A; Mordenti J; Brady S; Gillett N A; Chen S A; Ashkenazi A
Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(3):1347-53.
1993: Barfod E T; Zheng Y; Kuang W J; Hart M J; Evans T; Cerione R A; Ashkenazi A
Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain.
The Journal of biological chemistry 1993;268(35):26059-62.
1993: Haak-Frendscho M; Marsters S A; Chamow S M; Peers D H; Simpson N J; Ashkenazi A
Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin.
Immunology 1993;79(4):594-9.
1993: Pennica D; Lam V T; Weber R F; Kohr W J; Basa L J; Spellman M W; Ashkenazi A; Shire S J; Goeddel D V
Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor.
Biochemistry 1993;32(12):3131-8.
1992: Oksenberg D; Marsters S A; O'Dowd B F; Jin H; Havlik S; Peroutka S J; Ashkenazi A
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors.
Nature 1992;360(6400):161-3.
1992: Chamow S M; Kogan T P; Peers D H; Hastings R C; Byrn R A; Ashkenazi A
Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent.
The Journal of biological chemistry 1992;267(22):15916-22.
1992: Jin H; Oksenberg D; Ashkenazi A; Peroutka S J; Duncan A M; Rozmahel R; Yang Y; Mengod G; Palacios J M; O'Dowd B F
Characterization of the human 5-hydroxytryptamine1B receptor.
The Journal of biological chemistry 1992;267(9):5735-8.
1992: Marsters S A; Frutkin A D; Simpson N J; Fendly B M; Ashkenazi A
Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.
The Journal of biological chemistry 1992;267(9):5747-50.
1992: Chamow S M; Duliege A M; Ammann A; Kahn J O; Allen J D; Eichberg J W; Byrn R A; Capon D J; Ward R H; Ashkenazi A
CD4 immunoadhesins in anti-HIV therapy: new developments.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1992;7():69-72.
1991: Ashkenazi A; Marsters S A; Capon D J; Chamow S M; Figari I S; Pennica D; Goeddel D V; Palladino M A; Smith D H
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(23):10535-9.
1991: Ashkenazi A; Smith D H; Marsters S A; Riddle L; Gregory T J; Ho D D; Capon D J
Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(16):7056-60.
1990: Chamow S M; Peers D H; Byrn R A; Mulkerrin M G; Harris R J; Wang W C; Bjorkman P J; Capon D J; Ashkenazi A
Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments.
Biochemistry 1990;29(42):9885-91.
1989: Ashkenazi A; Peralta E G; Winslow J W; Ramachandran J; Capon D J
Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth.
Trends in pharmacological sciences 1989;Suppl():16-22.
1989: Ashkenazi A; Ramachandran J; Capon D J
Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes.
Nature 1989;340(6229):146-50.
1989: Ashkenazi A; Peralta E G; Winslow J W; Ramachandran J; Capon D J
Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell.
Cell 1989;56(3):487-93.
1989: Ramachandran J; Peralta E G; Ashkenazi A; Winslow J W; Smith D H; Capon D J
Structural and functional diversity of muscarinic acetylcholine receptor subtypes.
Progress in clinical and biological research 1989;289():327-39.
1988: Peralta E G; Ashkenazi A; Winslow J W; Ramachandran J; Capon D J
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes.
Nature 1988;334(6181):434-7.
1988: Peralta E G; Winslow J W; Ashkenazi A; Smith D H; Ramachandran J; Capon D J
Structural basis of muscarinic acetylcholine receptor subtype diversity.
Trends in pharmacological sciences 1988;Suppl():6-11.
1988: Ashkenazi A; Peralta E G; Winslow J W; Ramachandran J; Capon D J
Functional role of muscarinic acetylcholine receptor subtype diversity.
Cold Spring Harbor symposia on quantitative biology 1988;53 Pt 1():263-72.
1987: Peralta E G; Ashkenazi A; Winslow J W; Smith D H; Ramachandran J; Capon D J
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors.
The EMBO journal 1987;6(13):3923-9.
1987: Ashkenazi A; Winslow J W; Peralta E G; Peterson G L; Schimerlik M I; Capon D J; Ramachandran J
An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover.
Science (New York, N.Y.) 1987;238(4827):672-5.
1987: Peralta E G; Winslow J W; Peterson G L; Smith D H; Ashkenazi A; Ramachandran J; Schimerlik M I; Capon D J
Primary structure and biochemical properties of an M2 muscarinic receptor.
Science (New York, N.Y.) 1987;236(4801):600-5.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Avi Ashkenazi

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Concepts & Ideas

Genes & Molecular Sequences

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Avi Ashkenazi (preview)

All Publications